Skip to main content
Top
Published in: Rheumatology International 2/2017

01-02-2017 | Observational Research

Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study

Authors: Chien-Fang Huang, Ju-Chi Liu, Hui-Chuan Huang, Shao-Yuan Chuang, Chang-I Chen, Kuan-Chia Lin

Published in: Rheumatology International | Issue 2/2017

Login to get access

Abstract

The aim of the study was to investigate the longitudinal transition trajectory of gout and its comorbidities in male patients with gout in different age groups. A total of 3973 male patients who received a new diagnosis of gouty arthritis were identified from the Taiwan Longitudinal Health Insurance Database and divided into two age cohorts (<50 and ≥50 years). Each patient was individually followed from 2000 to 2009 to identify associated comorbidities, namely hypertension, hypercholesterolemia, diabetes mellitus, cardiovascular diseases, and chronic kidney disease. Two outcome measurements of stroke and all-cause cancer were further identified until 2010. The transition trajectory was divided into the following five phenotype groups: persistent hypertension combined with a high prevalence of various gout-related comorbidities, persistent hypercholesterolemia combined with a moderate prevalence of various gout-related comorbidities, persistent low prevalence of various gout-related comorbidities, moderate to high prevalence of various gout-related comorbidities, and low to high prevalence of various gout-related comorbidities. Although the younger and older patients had a similar longitudinal transition trajectory of gout-related comorbidities, the older patients had a higher 10-year likelihood of transition from a low or moderate to a high prevalence of various gout-related comorbidities. In addition, the incidences of stroke and all-cause cancer were higher in the groups with high and moderate to high prevalences of various gout-related comorbidities than in the other groups. The occurrence of gouty arthritis in different life stages can cause cluster effects involving varying degrees of comorbidities over time. The findings of the current study can provide additional knowledge and increase clinical awareness regarding the early assessment and management of gout-related comorbidities in clinical practice.
Literature
1.
go back to reference Chuang SY, Lee SC, Hsieh YT, Pan WH (2011) Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr 20:301–308PubMed Chuang SY, Lee SC, Hsieh YT, Pan WH (2011) Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to 2005–2008. Asia Pac J Clin Nutr 20:301–308PubMed
3.
go back to reference Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63:3136–3141CrossRefPubMed Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63:3136–3141CrossRefPubMed
4.
go back to reference Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRef Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRef
5.
go back to reference Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 62:170–180 Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 62:170–180
6.
go back to reference Mancia G, Grassi G, Borghi C (2015) Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin 31(Suppl 2):15–19CrossRefPubMed Mancia G, Grassi G, Borghi C (2015) Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin 31(Suppl 2):15–19CrossRefPubMed
7.
go back to reference Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813–2821CrossRefPubMed Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N (2010) Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 26:2813–2821CrossRefPubMed
8.
go back to reference Robinson PC, Merriman TR, Herbison P, Highton J (2012) Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology 52:118–126CrossRefPubMed Robinson PC, Merriman TR, Herbison P, Highton J (2012) Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology 52:118–126CrossRefPubMed
9.
go back to reference Singh JA, Strand V (2008) Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 67:1310–1316CrossRefPubMed Singh JA, Strand V (2008) Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 67:1310–1316CrossRefPubMed
10.
go back to reference Richette P, Clerson P, Perissin L, Flipo RM, Bardin T (2013) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 74:142–147CrossRefPubMed Richette P, Clerson P, Perissin L, Flipo RM, Bardin T (2013) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis 74:142–147CrossRefPubMed
11.
go back to reference Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA (2007) Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 7:220CrossRefPubMedPubMedCentral Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA (2007) Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 7:220CrossRefPubMedPubMedCentral
12.
go back to reference Jousilahti P, Vartiainen E, Tuomilehto J, Puska P (1999) Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 99:1165–1172CrossRefPubMed Jousilahti P, Vartiainen E, Tuomilehto J, Puska P (1999) Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 99:1165–1172CrossRefPubMed
13.
go back to reference Kim SY, De Vera MA, Choi HK (2008) Gout and mortality. Clin Exp Rheumatol 26(5 Suppl 51):S115–S119PubMed Kim SY, De Vera MA, Choi HK (2008) Gout and mortality. Clin Exp Rheumatol 26(5 Suppl 51):S115–S119PubMed
14.
go back to reference Krishnan E, Lingala B, Bhalla V (2012) Low-level lead exposure and the prevalence of gout: an observational study. Ann Intern Med 157:233–241CrossRefPubMed Krishnan E, Lingala B, Bhalla V (2012) Low-level lead exposure and the prevalence of gout: an observational study. Ann Intern Med 157:233–241CrossRefPubMed
15.
go back to reference Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC (2015) Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int 35:1799–1807CrossRefPubMedPubMedCentral Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC (2015) Patient and clinical characteristics associated with gout flares in an integrated healthcare system. Rheumatol Int 35:1799–1807CrossRefPubMedPubMedCentral
16.
go back to reference DeMarco MA, Maynard JW, Huizinga MM, Baer AN, Kottgen A, Gelber AC et al (2011) Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res 63:1108–1114CrossRef DeMarco MA, Maynard JW, Huizinga MM, Baer AN, Kottgen A, Gelber AC et al (2011) Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res 63:1108–1114CrossRef
17.
go back to reference Kumar S, Gupta R, Suppiah R (2012) Gout in women: differences in risk factors in young and older women. NZ Med J 125:39–45 Kumar S, Gupta R, Suppiah R (2012) Gout in women: differences in risk factors in young and older women. NZ Med J 125:39–45
18.
go back to reference Seminog OO, Goldacre MJ (2013) Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology 52:2251–2259CrossRefPubMed Seminog OO, Goldacre MJ (2013) Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology 52:2251–2259CrossRefPubMed
19.
go back to reference Hsing AW, Ioannidis JP (2015) Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 175:1527–1529CrossRefPubMed Hsing AW, Ioannidis JP (2015) Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. JAMA Intern Med 175:1527–1529CrossRefPubMed
20.
go back to reference Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS et al (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906–1914CrossRefPubMed Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS et al (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906–1914CrossRefPubMed
21.
go back to reference Harris MD, Siegel LB, Alloway JA (1999) Gout and hyperuricemia. Am Fam Phys 59:925–934 Harris MD, Siegel LB, Alloway JA (1999) Gout and hyperuricemia. Am Fam Phys 59:925–934
22.
go back to reference Collins LM, Lanza S (2010) Latent class and latent transition analysis with applications in the social, behavioral, and health sciences. Wiley, Hoboken Collins LM, Lanza S (2010) Latent class and latent transition analysis with applications in the social, behavioral, and health sciences. Wiley, Hoboken
23.
go back to reference Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M et al (2016) Anxiety and anxious-depression in Parkinson’s disease over a 4-year period: a latent transition analysis. Psychol Med 46:657–667CrossRefPubMed Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M et al (2016) Anxiety and anxious-depression in Parkinson’s disease over a 4-year period: a latent transition analysis. Psychol Med 46:657–667CrossRefPubMed
24.
go back to reference Soto-Ramirez N, Ziyab AH, Karmaus W, Zhang H, Kurukulaaratchy RJ, Ewart S et al (2013) Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability. J Epidemiol 23:399–410CrossRefPubMedPubMedCentral Soto-Ramirez N, Ziyab AH, Karmaus W, Zhang H, Kurukulaaratchy RJ, Ewart S et al (2013) Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability. J Epidemiol 23:399–410CrossRefPubMedPubMedCentral
25.
go back to reference Mathur C, Stigler MH, Erickson DJ, Perry CL, Forster JL (2014) Transitions in smoking behavior during emerging adulthood: a longitudinal analysis of the effect of home smoking bans. Am J Public Health 104:715–720CrossRefPubMedPubMedCentral Mathur C, Stigler MH, Erickson DJ, Perry CL, Forster JL (2014) Transitions in smoking behavior during emerging adulthood: a longitudinal analysis of the effect of home smoking bans. Am J Public Health 104:715–720CrossRefPubMedPubMedCentral
26.
go back to reference Maxwell AJ, Bruinsma KA (2001) Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 38:1850–1858CrossRefPubMed Maxwell AJ, Bruinsma KA (2001) Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 38:1850–1858CrossRefPubMed
27.
go back to reference Doehner W, Landmesser U (2011) Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 31:433–440CrossRefPubMed Doehner W, Landmesser U (2011) Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 31:433–440CrossRefPubMed
28.
go back to reference Puzserova A, Bernatova I (2016) Blood pressure regulation in stress: focus on nitric oxide-dependent mechanisms. Physiol Res 65(Supplementum 3):S309–S342PubMed Puzserova A, Bernatova I (2016) Blood pressure regulation in stress: focus on nitric oxide-dependent mechanisms. Physiol Res 65(Supplementum 3):S309–S342PubMed
29.
go back to reference Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ (1998) Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 14:241–249CrossRefPubMed Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ (1998) Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 14:241–249CrossRefPubMed
30.
go back to reference Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL (1999) Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 103:897–905CrossRefPubMedPubMedCentral Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL (1999) Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 103:897–905CrossRefPubMedPubMedCentral
31.
go back to reference Kruzliak P, Maruyama J, Maruyama K (2014) Role of nitric oxide in pathophysiology and treatment of pulmonary hypertension. Vitam Horm 96:407–424CrossRefPubMed Kruzliak P, Maruyama J, Maruyama K (2014) Role of nitric oxide in pathophysiology and treatment of pulmonary hypertension. Vitam Horm 96:407–424CrossRefPubMed
32.
go back to reference Perez-Ruiz F, Becker MA (2015) Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin 31(Suppl 2):9–14CrossRefPubMed Perez-Ruiz F, Becker MA (2015) Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin 31(Suppl 2):9–14CrossRefPubMed
33.
go back to reference Chen CJ, Yen JH, Chang SJ (2014) Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol 43:385–390CrossRefPubMed Chen CJ, Yen JH, Chang SJ (2014) Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol 43:385–390CrossRefPubMed
34.
go back to reference Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH (2012) Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine 79:375–378CrossRefPubMed Kuo CF, Luo SF, See LC, Chou IJ, Fang YF, Yu KH (2012) Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine 79:375–378CrossRefPubMed
35.
go back to reference Fini MA, Elias A, Johnson RJ, Wright RM (2012) Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Trans Med 1:16CrossRef Fini MA, Elias A, Johnson RJ, Wright RM (2012) Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Trans Med 1:16CrossRef
37.
go back to reference You J, Liu WY, Zhu GQ, Wang OC, Ma RM, Huang GQ et al (2015) Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget 6:19880–19890CrossRefPubMedPubMedCentral You J, Liu WY, Zhu GQ, Wang OC, Ma RM, Huang GQ et al (2015) Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget 6:19880–19890CrossRefPubMedPubMedCentral
38.
go back to reference Orengo JM, Leliwa-Sytek A, Evans JE, Evans B, van de Hoef D, Nyako M et al (2009) Uric acid is a mediator of the Plasmodium falciparum-induced inflammatory response. PLoS One 4:e5194CrossRefPubMedPubMedCentral Orengo JM, Leliwa-Sytek A, Evans JE, Evans B, van de Hoef D, Nyako M et al (2009) Uric acid is a mediator of the Plasmodium falciparum-induced inflammatory response. PLoS One 4:e5194CrossRefPubMedPubMedCentral
39.
go back to reference Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY (2005) Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. JFMA 104:157–163 Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY (2005) Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. JFMA 104:157–163
40.
go back to reference Hsieh CY, Chen CH, Li CY, Lai ML (2015) Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. JFMA 114:254–259 Hsieh CY, Chen CH, Li CY, Lai ML (2015) Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. JFMA 114:254–259
41.
go back to reference Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH (2014) Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol 24:500–507CrossRefPubMedPubMedCentral Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH (2014) Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol 24:500–507CrossRefPubMedPubMedCentral
42.
go back to reference Hung YN, Kadziola Z, Brnabic AJ, Yeh JF, Fuh JL, Hwang JP et al (2016) The epidemiology and burden of Alzheimer’s disease in Taiwan utilizing data from the National Health Insurance Research Database. Clinicoecon Outcomes Res 8:387–395CrossRefPubMedPubMedCentral Hung YN, Kadziola Z, Brnabic AJ, Yeh JF, Fuh JL, Hwang JP et al (2016) The epidemiology and burden of Alzheimer’s disease in Taiwan utilizing data from the National Health Insurance Research Database. Clinicoecon Outcomes Res 8:387–395CrossRefPubMedPubMedCentral
43.
go back to reference Hsu CC, Wang H, Hsu YH, Chuang SY, Huang YW, Chang YK et al (2015) Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension 66:524–533CrossRefPubMed Hsu CC, Wang H, Hsu YH, Chuang SY, Huang YW, Chang YK et al (2015) Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension 66:524–533CrossRefPubMed
44.
go back to reference Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17:13CrossRefPubMed Abeles AM (2015) Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep 17:13CrossRefPubMed
45.
go back to reference Akkineni R, Tapp S, Tosteson AN, Lee A, Miller KL, Choi HK et al (2014) Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol 41:739–748CrossRefPubMed Akkineni R, Tapp S, Tosteson AN, Lee A, Miller KL, Choi HK et al (2014) Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol 41:739–748CrossRefPubMed
Metadata
Title
Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study
Authors
Chien-Fang Huang
Ju-Chi Liu
Hui-Chuan Huang
Shao-Yuan Chuang
Chang-I Chen
Kuan-Chia Lin
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3634-9

Other articles of this Issue 2/2017

Rheumatology International 2/2017 Go to the issue